本則回應

• Ann標記此篇為：❌ 含有不實訊息

  理由

  此訊息節錄部分，與連結中文章實際立場相反，為斷章取義。
  
  1. 2021年刊登於《JAMA》的研究，不支持使用伊維菌素治療COVID-19輕症，該研究確實接受默克藥廠（Merck）、吉利德科學公司、楊森製藥（Janssen）、賽諾菲巴斯德等公司贊助，但一切均在研究發表時，公開記載於「
  
  閱讀更多

  出處

  Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19
  https://jamanetwork.com/journals/jama/fullarticle/2777389
  
  Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities
  https://jamanetwork.com/journals/jamaint⋯tm_links&utm_content=tfl&utm_term=021822
  
  伊維菌素對COVID-19療效佳？ 莊人祥：無證據支持
  https://www.cna.com.tw/news/ahel/202111030180.aspx
  
  【查證】服用伊維菌素後，巴西、秘魯、印度疫情大幅下降？各國狀況與專家解析
  https://www.mygopen.com/2021/08/Ivermectin-news.html

  Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19

  https://jamanetwork.com/journals/jama/fullarticle/2777389

  This randomized trial compares the effects of ivermectin vs placebo on time to symptom resolution within 21 days among patients with mild COVID-19.

  Efficacy of Ivermectin on Disease Progression in Patients With COVID-19

  https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2789362?guestAccessKey=58760460-df0f-4790-9257-8f3682dca39b&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=021822

  This randomized clinical trial assesses the efficacy of ivermectin treatment in preventing progression to severe disease among high-risk patients with COVID-19 in Malaysia.

  伊維菌素對COVID-19療效佳？ 莊人祥：無證據支持 | 生活 | 中央社 CNA

  https://www.cna.com.tw/news/ahel/202111030180.aspx

  國內專家認為抗寄生蟲老藥「伊維菌素」對治療COVID-19療效佳。指揮中心今天說，所有證據不支持伊維菌素可用於預防或治療COVID-19，目前此藥為專案進口，未納入指引。

  【查證】服用伊維菌素後，巴西、秘魯、印度疫情大幅下降？各國狀況與專家解析

  https://www.mygopen.com/2021/08/Ivermectin-news.html

  網傳「服用伊維菌素後，巴西、秘魯、印度疫情大幅下降」的訊息。專家指出，過去有部分文章指稱伊維菌素好像對控制新冠肺炎有幫助，但從比較嚴謹的醫學角度、實證醫學看來，目前沒有足夠證據認為伊維菌素有幫助，所以未被納入正式的治療指引。專家表示，即使是在真實世界進行的試驗，仍要看該研究做得夠不夠嚴謹，需考量很多